AI monitors, determines age of preterm infant brain

Researchers from the University of Helsinki and the Helsinki University Hospital have developed artificial intelligence (AI) software capable of measuring EEG signals in preterm infants to estimate the brain's functional maturity, according to a study published in Scientific Reports.

One in 10 live births occur prematurely, interrupting the late pregnancy development of the fetus’s brain. In this study, researchers utilized AI to make more precise evaluations of the development of an infant’s brain and monitor its progression.

"We currently track the development of an infant's weight, height and head circumference with growth charts. EEG monitoring combined with automatic analysis provides a practical tool for the monitoring of the neurological development of preterm infants and generates information which will help plan the best possible care for the individual child," said Sampsa Vanhatalo from the University of Helsinki, who led the research. "This method gives us a first-time opportunity to track the most crucial development of a preterm infant, the functional maturation of the brain, both during and after intensive care."

The analysis software used a large amount of data on EEG measurement from preterm infants, collected from the Medical University of Vienna. Once trained, the software was able to calculate computational features from each measurement without intervention. Along with a machine algorithm, the software was able to identify the EEG age of the infant in 80 percent of cases.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.